The online hub for digital CME and CE courses
The ONA Forum consultants answer your questions
View articles about patient-focused care
No significant difference in morbidity, cancer control for men treated post-prostatectomy using Intensity-modulated radiotherapy (IMRT) over conformal radiotherapy (CRT).
Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to recently published data.
For older men with nonmetastatic prostate cancer, comorbidities increase risk of other-cause death mortality.
Men with prostate cancer who used statin drugs prior to diagnosis had a decreased risk of prostate-cancer-specific mortality.
High fitness has been linked to reductions in risk of developing and dying from lung, colorectal cancer.
A new tool helps identify men who are best suited for active surveillance of prostate cancer, predicting which are more likely to harbor an aggressive form of the disease.
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men, and they were at a greater risk for subsequently developing prostate cancer, according to a new study.
The FDA has approved Xofigo (radium Ra 223 dichloride; Bayer) for the treatment of symptomatic late-stage castration-resistant prostate cancer with bone metastases.
Significant associations seen in men's urinary and sexual function based on surgeon performing radical prostatectomy.
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.
Patients with metastatic prostate cancer who visit ER over the weekend have increased odds of death, compared with weekday visits.
According to a recent retrospective study, the protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer.
Sequencing of 57 prostate cancer genomes found that cancer gains a powerful advantage with abrupt intervals of complex, large-scale DNA reshuffling. This process has been dubbed punctuated cancer evolution.
New guidelines from the American Urological Association advise men aged 55 to 69 years who are considering prostate cancer screening to talk with their doctors about the benefits and harms of testing.
Many older men who are found to have prostate cancer after PSA screening receive treatment despite advancing age, poor health, or low-risk disease.
Hereditary mutations in the BRCA2 gene predispose patients to a worse evolution of prostate cancer and a greater risk of developing metastasis.
The American College of Physicians (ACP) recommends against prostate-specific antigen (PSA) screening for men older than age 69 and many others.
In men with an initial benign biopsy, obesity at the time of the procedure is associated with the presence of precancerous lesions in the initial biopsy and a higher risk of developing prostate cancer.
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study.
Late recurrence of prostate cancer is rare if PSA is less than 0.2 ng/mL, the surgical PSA definition of cancer control, 15 years after treatment with radiation therapy.
African American men on average wait a week longer than their Caucasian counterparts between the initial diagnosis of prostate cancer and treatment, according to a new study.
Baldness was associated with an increased risk of prostate cancer among African American men, and risk for advanced prostate cancer increased with younger age and type of baldness, according to recently published data.
Intermittent androgen deprivation is linked to worse survival versus continuous; however, the results were statistically inconclusive.
Researchers have identified a mechanism in androgen-insensitive prostate cancer cells that enables them to survive treatment. A protein called Siah2 keeps a portion of androgen receptors constantly active in prostate cancer cells.
The digital rectal examination is an important screening test that can discover prostate cancer that a PSA test may not, despite the higher sensitivity of the PSA test.
Surgery offers a better survival benefit for men with localized prostate cancer, according to a large observational study.
A JCO study has found that Lynch syndrome carriers have an almost two-fold cumulative chance of prostate cancer at ages 60 and 80 years.
A recent study showed the promising benefit of multipeptide vaccination therapy combined with low-dose dexamethasone in patients who are chemotherapy-naïve or those not yet exposed to specific antigens.
Genistein-combined polysaccharide, a natural and nontoxic product available in health food stores, could help lengthen life expectancy for patients with prostate cancer.
Researchers assessed why two studies comparing prostatectomy with watchful waiting had conflicting findings in absolute mortality difference.
A posttreatment assessment of men who underwent treatment for prostate cancer revealed a side effect that has a significant impact on patients.
Men with early-stage prostate cancer may be able to inhibit tumor growth and progression by following a high-fiber diet.
Anticoagulant use is associated with improved survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.
Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, found research presented at the 2013 Genitourinary Cancers Symposium.
Differences in urinary, bowel, and sexual function were reported at short-term follow-up, but those differences were no longer significant 15 years after initial treatment.
Behavioral stress can accelerate the development of prostate cancer and weaken the effectiveness of drugs designed to fight the disease.
Overall treatment time for prostate cancer was reduced by about 14% by the use of VMAT to deliver intensity-modulated radiation therapy.
Men with a high risk of bone fracture who are receiving long-term ADT for prostate cancer have a higher fracture incidence after their treatment is completed. Also, men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not.
Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results.
Over two-year follow-up, more cancers detected in men in dutasteride arm versus placebo arm.
A recent study showed evaluating prostate-specific antigen measurements taken over time improves the accuracy of aggressive prostate cancer detection compared with a single measurement of PSA.
A posttreatment assessment of men who underwent treatment for prostate cancer revealed a side effect that has a significant impact on patients.
An updated version of the Partin Tables, a tool to help men with prostate cancer and their doctors better assess the chance of a surgical cure, has been developed.
Physicians' practice styles related to informed decision-making for prostate-specific antigen (PSA) screening are linked to their personal beliefs about screening.
Elevated levels of the cell cycle regulator cyclin D1b may be a novel biomarker of lethal metastatic disease in men with prostate cancer.
Creating T cells that recognize two different antigens on a tumor cell rather than just one could lead to more precisely targeted immunotherapy.
Low incidence, but more likely after surgery or radiotherapy plus ADT versus radiotherapy alone.
Most men would not have chosen a different treatment even if they had been aware of costs.
Traditionally, prostate cancer has been found only by blind biopsy using transrectal ultrasound to sample the prostate. It is the only major malignancy diagnosed without actually visualizing the tumor during biopsy.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
A clinic-based technique of targeted biopsy using MRI and ultrasound may improve the diagnosis and management of prostate cancer.
About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12% seeing complete resolution on uptake on bone scans.
May accelerate progression in cases of PTEN-loss induced high-grade prostatic intraepithelial.
Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Magnetic resonance-ultrasound fusion targeted biopsy detects aggressive tumors better than standard.
U.S. Food and Drug Administration approval of Zytiga (abiraterone acetate) has been expanded to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy, the agency said today.
Men have a surprising lack of awareness about prostate cancer, according to results of a new survey. A significant gap exists between the facts about prostate cancer and what men believe about the disease.
Cloud technology is now being used to collect detailed information from thousands of cancer samples with the goal of helping doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.
Levels of circulating tumor cells and of prostate specific antigen were reduced by a new drug in patients who had already failed previous chemotherapy and hormone treatments.
Two separate research teams identified genes that can predict outcomes in men with castration-resistant prostate cancer (CRPC).
Proton therapy preserves quality of life, meaning specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer. This research obtained information directly from the men who underwent the therapy, rather than from their treatment providers.
Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.
Only 4.8% of websites describing prostate cancer are written below a high school reading level. Their median reading level was 12th grade. Notably, the NIH recommends that patient-education materials be written at the fourth-through-sixth grade reading level.
Scientists discovered PARP-1 contributes to the growth and progression of androgen receptor-positive prostate cancer cells.
Study findings suggest that public health recommendations regarding diet and lifestyle to prevent heart disease and diabetes may also decrease a man's likelihood of dying from prostate cancer.
Certain analyses of cancer cells isolated from the blood could guide decisions about the ideal treatment for a patient with metastatic prostate cancer who has stopped responding to initial therapy.
New insights into the action of taxanes on androgen receptors in prostate cancer shed light on why a patient may not respond to these drugs.
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
State of androgen receptor signaling may help determine best treatment.
Compared with prostatectomy, surveillance will likely reduce prostate cancer-specific survival only slightly and greatly enhance quality of life.
Researchers have identified 12 genetic markers linked with susceptibility for erectile dysfunction after radiotherapy for prostate cancer.
A protein that confers a worse prognosis in bladder cancer when present in high levels may respond to antiandrogen therapy used in prostate cancer.
In 2008, total disability-adjusted life-years lost mainly due to colorectal, lung, breast, prostate cancer.
A six-gene signature has been identified that can be used in a test to predict survival in men with aggressive prostate cancer.
Abiraterone markedly prolongs survival in men with metastatic castration-resistant prostate cancer that has progressed after docetaxel therapy.
Two studies identify prognostic profiles for men with castration-resistant prostate cancer.
Adding endorectal magnetic resonance imaging (MRI) to the initial clinical evaluation of men with clinically low-risk prostate cancer helps to assess eligibility for active surveillance.
Adult cancer survivors have concerns about receiving cancer-related follow-up care from their primary-care physicians (PCPs).
Contrast-enhanced ultrasonography detects high-grade prostate cancer better than conventional methods, and so it is a more appropriate approach for screening clinically important cancers and monitoring low-risk ones with fewer biopsies.
One year after men undergo surgical removal of prostate cancer, they have significant anxiety, which appears to be linked to poor sexual satisfaction and depression.
Simulation model compares long-term effect of active surveillance versus immediate prostatectomy.
Intermittent androgen deprivation was just as effective as continuous therapy in overall survival, and improved some quality-of-life factors.
The anti-estrogen tamoxifen appears to suppress gynecomastia and breast pain in men undergoing androgen-suppression therapy for prostate cancer.
Findings in patients with metastatic castration-resistant prostate cancer.
Overall survival rates have improved for men with prostate cancer following the introduction of PSA screening, particularly for African Americans.
Aspirin primarily contributes to reduction for localized cancer treated with prostatectomy, radiotherapy.
The magnitude of change in serum prostate-specific antigen (PSA) after 5α-reductase inhibitor therapy may be useful in diagnosing prostate cancer.
Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Survival rates comparable for white and black men in post-prostate-specific antigen era trial.
Patient information on coping with the emotional toll of cancer, making treatment decisions, dietary and nutritional needs, and survivorship care
Men undergoing expectant management have high compliance with RAND structural indicators.
The protein paxillin can regulate signals that lead to the creation of prostate cancer cells even in the absence of tumor-nurturing hormones.
Post-chemo, enzalutamide also improves secondary outcomes in metastatic castration-resistant cancer.
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
Findings are in men with persistently increased serum PSA and previously negative prostate biopsies.
Radical prostatectomy did not significantly reduce all-cause or prostate cancer mortality compared with observation in men with localized disease.
An ultrasound-based therapy that agitates blood vessels has been shown to enhance the tumor-blasting effects of radiation by 10-fold in experiments.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
